港股新上市公司佰泽医疗（02609）今日盘中大涨22.99%，引发市场广泛关注。作为中国主要的肿瘤医疗集团，佰泽医疗的强劲表现凸显了投资者对肿瘤医疗服务行业的信心。
佰泽医疗此次全球发售约1.33亿股，最终以每股4.22港元的发行价完成募资，净筹资约4.68亿港元。公司公开发售部分获得25.92倍超额认购，显示出投资者对其前景的看好。上市首日开盘价为5.25港元，较发行价上涨24.41%，截至发稿时涨幅为22.99%。
作为专注于提供肿瘤全周期医疗服务的集团，佰泽医疗在北京、天津、山西省、安徽省及河南省运营和管理八家医院。公司通过与北京大学肿瘤医院、天津市石学敏中医发展基金会等机构合作，获得了高质量的医疗资源支持，提升了其在肿瘤诊疗和康复领域的竞争力。
分析人士指出，佰泽医疗股价的强劲表现反映了市场对严肃医疗服务的需求和认可。在人口老龄化趋势下，肿瘤防治需求持续增长，为专业的肿瘤医疗服务提供商带来了广阔的发展空间。此外，公司在早期癌症筛查、AI技术应用等方面的布局，也增强了投资者对其未来发展潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.